Integra Lifesciences Holdings Corp

IART is in a Stage 2 advancing trend with a clear sequence of higher highs and higher lows, supported by rising short-term EMAs and the 50 DMA. Price is consolidating just above EMAs without signs of exhaustion, presenting a favorable pullback entry. The Medium-Term bias is bullish and permits long-side engagement, while the Long-Term trend remains structurally bearish. Execution is recommended now on pullbacks into the rising 9/21 EMA zone. Key risk is a breakdown below the 50 DMA on heavy volume, which would invalidate the bullish bias.

• ↑Q1 rev $392M (+2.4% YoY) with adj EPS $0.54 (+31.7%)
• ↑Gross margin rose to 64.1%, reflecting improved efficiencies
• ↓Negative growth and profitability factors signal execution risk